WO1994006498A1 - Inhalation device - Google Patents

Inhalation device Download PDF

Info

Publication number
WO1994006498A1
WO1994006498A1 PCT/GB1993/002013 GB9302013W WO9406498A1 WO 1994006498 A1 WO1994006498 A1 WO 1994006498A1 GB 9302013 W GB9302013 W GB 9302013W WO 9406498 A1 WO9406498 A1 WO 9406498A1
Authority
WO
WIPO (PCT)
Prior art keywords
capsule
medicament
inhalation device
air inlet
movement
Prior art date
Application number
PCT/GB1993/002013
Other languages
French (fr)
Inventor
Michael Trevor Shepherd
Alastair Robert Clarke
Bruce James Renfrew
Original Assignee
Fisons Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929220077A external-priority patent/GB9220077D0/en
Priority claimed from GB929220083A external-priority patent/GB9220083D0/en
Application filed by Fisons Plc filed Critical Fisons Plc
Priority to AU48295/93A priority Critical patent/AU4829593A/en
Publication of WO1994006498A1 publication Critical patent/WO1994006498A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0028Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033Details of the piercing or cutting means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/06Solids
    • A61M2202/064Powder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2206/00Characteristics of a physical parameter; associated device therefor
    • A61M2206/10Flow characteristics
    • A61M2206/14Static flow deviators in tubes disturbing laminar flow in tubes, e.g. archimedes screws

Definitions

  • This invention relates to inhalation devices and in particular to devices for the inhalation of powdered medicament contained in capsules.
  • powdered medicament is often supplied in capsules which are loaded into a dispensing device wherein the medicament is released from the capsule then inhaled by the patient.
  • GB 1122284 discloses one such device for the inhalation of powdered medicament from a capsule, a preferred embodiment of this device is sold o under the name SPINHALERTM.
  • This device has the disadvantage that it must be dismantled for insertion of a capsule prior to inhalation and again to remove the empty capsule after inhalation. Dismantling the device can prove very difficult especially for those with impaired hand movement such as the elderly.
  • a medicament inhalation device including a housing defining a through-going pathway provided at one end with an air inlet, and at the other end with a mouthpiece; a drive member rotatably mounted in the housing on a shaft which is coaxial with the longitudinal axi o of the housing, the drive member having, on a portion adjacent to the air inlet, mounting means adapted to engage a medicament capsule, and the drive member being so mounted on the shaft that the passage of a stream of air through the pathway causes rotational and vibrational movement of the drive member; characterised in that the air inlet is adapted to act as a capsule port through which a 5 capsule can be inserted into the mounting means.
  • the device according to the invention preferably includes release means to permit removal of a capsule from the mounting means through the air inlet. -.
  • Drive members suitable for use in the device according to the invention 0 include propellers having two or more rotor vanes or blades symmetrically disposed about a central axis or hub, such that impingement of an air stream on the rotor vanes or blades causes rotation of the propeller about the axis or hub.
  • the drive member preferably includes a sleeve-like bearing for mounting over the shaft of the device.
  • the drive member may be freely mounted on the shaft, however, we prefer the drive member to be retained on the shaft by retaining means
  • the retaining means may comprise a circumferential ridge formed on the interior wall of the sleeve-like bearing which is received by a circumferential recess formed on the shaft or vice versa.
  • the retaining means prevents the drive member falling of the shaft if the device needs to be dismantled, e.g. for cleaning.
  • the vibrational component of the movement of the drive member is essential for release of medicament from the capsule and to obtain constant and reproducible results from the inhalation device.
  • Vibrational movement of the drive member may be effected by controlling the dimensions of said member as described in GB 1122284 and GB 1301856 (Fisons pic) the disclosures of which are incorporated herein by reference.
  • the device according to the invention preferably includes piercing means for piercing a capsule held in the mounting means.
  • Suitable piercing mechanisms will b apparent to those skilled in the art and include e.g. pins or blades.
  • the piercing means preferably takes the form of one or more, e.g. two, spring biassed pins.
  • Piercing of the capsule may be effected by a cam surface moving over the spring biassed pins, the reciprocal movement of the cam surface allowing the pins to withdraw from the capsule under their spring bias.
  • cam surfaces these are preferably provided on the inside of a sleeve slidably mounted on the housing of the device.
  • the device may be used for dispensing medicament contained i pre-pierced capsules, i.e. capsules the walls of which are provided with one or more apertures during manufacture; in this case it is not necessary for the device to includ piercing means.
  • the air inlet of the device must be large enough to enable it to function as capsule port for the insertion of a medicament capsule into the mounting means.
  • the air inlet preferably comprises a circular aperture having a diameter slightly larger than the diameter of a capsule to be inserted into the mounting means.
  • the device may be provided with additional air inlets, for example, positioned radially around the capsule port air inlet.
  • the housing of the device may act to guide a capsule inserted through the air inlet into the mounting means, this may be achieved by providing a constriction in the housing between the air inlet and the mounting means. This constriction may .. also act to restrict the air stream which flows through the pathway upon inhalation b a patient at the mouthpiece, thus increasing the velocity of air past the capsule and aiding in the release of medicament therefrom.
  • the mounting means preferably includes resilient jaws adapted engage a medicament capsule.
  • the drive member includes rotor vanes these are preferably integrally moulded with the resilient jaws of the mounting means.
  • the device according to the invention preferably includes release means and mounting means including resilient jaws, wherein movement of the release means from a first position to a second position disengages the capsule from the mounting means. Movement of the release means from a first position to a second position may either move the jaws from an engaged to a disengaged position, or transport the capsule from an engaged to a disengaged position.
  • the release means When the drive member includes rotor vanes integrally moulded with the resilient jaws then movement of the release means from a first (rest) position to a second (release) position preferably urges the rotor vanes away from the air inlet thereby causing jaws to move from an engaged to a disengaged position.
  • the release means transports the capsule from an engaged to a disengaged position, the release means preferably includes an ejection arm which is adapted to urge the capsule out of the mounting means and through the air inlet. In a first (rest) position the ejection arm will be retracted from the mounting means an upon movement to a second (release) position will slide up inside the mounting means thereby ejecting the capsule. Movement of the ejection arm may be effected by an expulsion collar slidably mounted on the drive member.
  • the device according to the invention includes release means movement of the release means from a first to a second position is preferably effected by a sleeve slidably mounted on the housing.
  • the sleeve preferably performs the dual function of moving the release means and actuating piercing means. Therefore, in a preferred embodiment of the device, movement of the sleeve from a rest position in a direction parallel to the longitudinal axis of housing actuates piercing means for piercing a capsule held in the mounting means; and movement of the sleeve from the rest position in the opposite direction moves the release means from a first position to a second position.
  • the device comprises release means this is preferably biased into a - first position, i.e a rest position in which a capsule can be inserted into, and engaged by, the mounting means.
  • the device may, if desired, be fitted with a non-return valve so that air may only be inhaled and not blown through the device by the patient.
  • the device may be constructed of any suitable material, preferably of a synthetic thermoplastic resin, e.g. high density polyethylene, acrylonitrile butadiene styrene (ABS), or DELRINTM; in which case it can be made by an injection moulding technique.
  • a synthetic thermoplastic resin e.g. high density polyethylene, acrylonitrile butadiene styrene (ABS), or DELRINTM; in which case it can be made by an injection moulding technique.
  • the capsules for use with the device according to the invention are preferably cylindrical, they may be made from any material which can be pierced, e.g. gelatin.
  • the device may be used for dispensing any powdered medicament which is conventionally administered by inhalation to the lung or nose.
  • medicaments include drugs for use in the prophylactic or remedial treatment of reversible obstructive airways disease.
  • Specific medicaments which may be mentioned include, for example, sodium cromoglycate and nedocromil sodium; inhaled steroids such as beclomethasone dipropionate, tipredane, and fluticasone; anticholinergic agents such as ipratropium bromide; bronchodilators, e.g. salmeterol, salbutamol, reproterol, terbutaline, albuterol and fenoterol; and salts thereof.
  • bronchodilators e.g. salmeterol, salbutamol, reproterol, terbutaline, albuterol and fenoterol
  • salts thereof e.g. salmeterol, salbutamol, reproterol, terbutaline,
  • Devices according to the invention have advantages over known inhalation devices in that the procedures for insertion of the medicament capsule into the device, and for removal of the empty capsule from the device after inhalation, are considerably simplified. Furthermore, since the device does not need to be dismantled for insertion/removal of the capsule, the patient is less likely to inadvertently injure themselves on the piercing means; and the propeller-like member, if freely mounted on the shaft, cannot fall off the shaft during the insertion/removal procedure.
  • Figure 1 is a perspective view of a device according to the invention.
  • Figure 2 is a longitudinal section of the device of Figure 1 in the rest position
  • Figure 3 is a section along the line III-III of Figure 2;
  • Figure 4 is a longitudinal section of the device of Figure 1 in the release position;
  • Figure 5 is a perspective view of an alternative device according to the invention.
  • Figure 6 is a longitudinal section of the device of Figure 5 in the rest position
  • Figure 7 is a section along the line VII- VII of Figure 6;
  • Figure 8 is a longitudinal section of the device of Figure 5 in the release position
  • a medicament inhalation device comprises a generally cylindrical housing (1) describing a through-going pathway.
  • the housing (1) is provided at one end with a mouthpiece portion (2), optionally having a removable mouthpiece cover (not shown), and provided at the other end with an air inlet (3).
  • a shaft (4) is rigidly mounted coaxially with the housing (1), the end of shaft (4) adjacent to the mouthpiece (2) end of housing (1) being supported by cross members (5).
  • Propeller (6) having a sleeve-like bearing (7) is mounted on shaft (4).
  • Shaft (4) is provided with a circumferential recess (8) which receives a circumferential ridge (9) formed on the interior wall of bearing (7) such that dissociation of the shaft (4) and the propeller (6) is prevented.
  • Propeller (6) is provided with a capsule mounting cup (10) comprising four resilient segments (11), shown best in Figure 3, which is adapted of engage a capsule (12) containing powdered medicament to be inhaled.
  • Propeller (6) is also provided with four rotor vanes (13) integrally moulded with segments (11), which cause the propeller (6) to rotate on shaft (4) when air is drawn through the pathway, as during inhalation. ..
  • Two stainless steel piercing needles (14), spring biased into the rest position s shown in Figures 2, are provided on housing (1).
  • One end of each needle (14) being secured to the housing (1), the other end being curved inwards such that they point towards a capsule (12) engaged by segments (11) of cup (10).
  • a sleeve (15) is slidably mounted on housing (1).
  • cam surfaces may be integrally moulded with the sleeve, however, for ease of manufacture they may be moulded separately and located in the sleeve during assembly of the device).
  • sleeve (15) turns inwards on itself thus s defining the walls of the air inlet (3).
  • Sleeve (15) extends further within housing (1) to form a circular release collar (17) which is located between the air inlet (3) and rotor vanes (13).
  • the collar (17) is adapted to apply downwards pressure onto rotor vanes (13) thus urging them away from the air inlet (3), thereby causing the segments (11) of cup 0 (10) to splay outwards.
  • the air inlet end of sleeve (15) urges needles (14) slightly inwards against their bias, this effect may be further enhanced by the provision of cam surfaces within the sleeve.
  • a capsule (12) containing powdered medicament to be inhaled is inserted through air inlet (3) and engaged by the segments (11) of cup (10).
  • Sleeve 5 (15) is then moved in the direction of arrow A in Figure 2 causing the cam surfaces
  • the patient then inhales through mouthpiece (2), thereby drawing air 0 through the pathway in the direction of arrow B in Figure 2.
  • the flow of air through the pathway causes the propeller (6) to rotate about shaft (4) and also to vibrate.
  • the medicament is thereby dispensed from capsule (12) through the apertures formed by needles (14), entrained in the air flow and inhaled by the patient.
  • the device is held with the air inlet (3) pointing downwards and sleeve (15) is moved over housing (1) in the direction of arrow C in Figure 4 (this may be achieved by pushing the sleeve and .. mouthpiece towards each other).
  • release collar (17) presses onto rotor vanes (13), s the pressure on rotor vanes (13) causing segments (11) to splay outwards from the base of cup (10) thus disengaging the empty capsule (12) which falls out of the housing (1) through the air inlet, as shown in Figure 4.
  • the sleeve (15) then returns to its rest position under the bias of needles (14) and the inhalation device is once more ready for use.
  • the release means includes a cylindrical ejection collar (18) slidably mounted around the housing (1).
  • the collar (18) is provided with projecting lugs (19) which cooperate with corresponding lugs (20) provided on the inside of sleeve (15).
  • Ejection collar (18) is also provided with two transverse arms (21) which project into housing (1). s Arms (21) abut against the base of a secondary ejection collar (22) slidably mounted around sleeve-like bearing (7). The secondary ejection collar (22) has two arms (23) running parallel to bearing (7) which extend through the base of mounting cup (10). Ejection collar (18) is biased into the rest position shown in Figure 6 by spring (24). In use, a capsule (12) containing medicament to be inhaled is inserted o through air inlet (3) and engaged by the segments (11) of cup (10). Sleeve (15) is then moved in the direction of arrow D in Figure 6 causing the cam surfaces (16) to engage needles (14) and pierce capsule (12).
  • sleeve (15) is moved in the direction of arrow E in Figure 8, lugs (19, 20) slide the ejection collar (18) over housing (1) against the bias of spring 5 (24).
  • the arms (21) of the ejection collar (18) push the secondary ejection collar (22) up the bearing (4) and arms (23) are raised into cup (10) thereby ejecting the empty capsule (12) out of the housing (1) through the air inlet (23).
  • the sleeve (15) then returns to its rest position under the bias of spring (24) and the inhalation device is once more ready for use.

Abstract

A medicament inhalation device including a housing (1) defining a throughgoing pathway provided at one end with an air inlet (3), and at the other end with a mouthpiece (2); a drive member (6) rotatably mounted in the housing (1) on a shaft (4) which is coaxial with the longitudinal axis of the housing (1), the drive member (6) having, on a portion adjacent to the air inlet (3), mounting means (10) adapted to engage a medicament capsule (12), and the drive member (6) being so mounted on the shaft (4) that the passage of a stream of air through the pathway causes rotational and vibrational movement of the drive member (6); characterised in that the air inlet (3) is adapted to act as a capsule port through which a capsule (12) can be inserted into the mounting means (10).

Description

INHALATION DEVICE
This invention relates to inhalation devices and in particular to devices for the inhalation of powdered medicament contained in capsules.
The administration of inhalation medicaments in dry powder form is well 5 known. Powdered medicament is often supplied in capsules which are loaded into a dispensing device wherein the medicament is released from the capsule then inhaled by the patient.
GB 1122284 (Fisons pic) discloses one such device for the inhalation of powdered medicament from a capsule, a preferred embodiment of this device is sold o under the name SPINHALER™. This device has the disadvantage that it must be dismantled for insertion of a capsule prior to inhalation and again to remove the empty capsule after inhalation. Dismantling the device can prove very difficult especially for those with impaired hand movement such as the elderly.
We have now devised an improved inhalation device which overcomes or s substantially mitigates the disadvantages of the device described above.
According to the present invention, there is provided a medicament inhalation device including a housing defining a through-going pathway provided at one end with an air inlet, and at the other end with a mouthpiece; a drive member rotatably mounted in the housing on a shaft which is coaxial with the longitudinal axi o of the housing, the drive member having, on a portion adjacent to the air inlet, mounting means adapted to engage a medicament capsule, and the drive member being so mounted on the shaft that the passage of a stream of air through the pathway causes rotational and vibrational movement of the drive member; characterised in that the air inlet is adapted to act as a capsule port through which a 5 capsule can be inserted into the mounting means.
In addition, the device according to the invention preferably includes release means to permit removal of a capsule from the mounting means through the air inlet. -.
Drive members suitable for use in the device according to the invention 0 include propellers having two or more rotor vanes or blades symmetrically disposed about a central axis or hub, such that impingement of an air stream on the rotor vanes or blades causes rotation of the propeller about the axis or hub. The drive member preferably includes a sleeve-like bearing for mounting over the shaft of the device. The drive member may be freely mounted on the shaft, however, we prefer the drive member to be retained on the shaft by retaining means
The retaining means may comprise a circumferential ridge formed on the interior wall of the sleeve-like bearing which is received by a circumferential recess formed on the shaft or vice versa. The retaining means prevents the drive member falling of the shaft if the device needs to be dismantled, e.g. for cleaning.
The vibrational component of the movement of the drive member is essential for release of medicament from the capsule and to obtain constant and reproducible results from the inhalation device. Vibrational movement of the drive member may be effected by controlling the dimensions of said member as described in GB 1122284 and GB 1301856 (Fisons pic) the disclosures of which are incorporated herein by reference.
The device according to the invention preferably includes piercing means for piercing a capsule held in the mounting means. Suitable piercing mechanisms will b apparent to those skilled in the art and include e.g. pins or blades. The piercing means preferably takes the form of one or more, e.g. two, spring biassed pins.
Piercing of the capsule may be effected by a cam surface moving over the spring biassed pins, the reciprocal movement of the cam surface allowing the pins to withdraw from the capsule under their spring bias. When piercing is effected by means of cam surfaces these are preferably provided on the inside of a sleeve slidably mounted on the housing of the device.
Alternatively the device may be used for dispensing medicament contained i pre-pierced capsules, i.e. capsules the walls of which are provided with one or more apertures during manufacture; in this case it is not necessary for the device to includ piercing means.
The air inlet of the device must be large enough to enable it to function as capsule port for the insertion of a medicament capsule into the mounting means.
The air inlet preferably comprises a circular aperture having a diameter slightly larger than the diameter of a capsule to be inserted into the mounting means. The device may be provided with additional air inlets, for example, positioned radially around the capsule port air inlet. The housing of the device may act to guide a capsule inserted through the air inlet into the mounting means, this may be achieved by providing a constriction in the housing between the air inlet and the mounting means. This constriction may .. also act to restrict the air stream which flows through the pathway upon inhalation b a patient at the mouthpiece, thus increasing the velocity of air past the capsule and aiding in the release of medicament therefrom.
The mounting means preferably includes resilient jaws adapted engage a medicament capsule. When the drive member includes rotor vanes these are preferably integrally moulded with the resilient jaws of the mounting means. The device according to the invention preferably includes release means and mounting means including resilient jaws, wherein movement of the release means from a first position to a second position disengages the capsule from the mounting means. Movement of the release means from a first position to a second position may either move the jaws from an engaged to a disengaged position, or transport the capsule from an engaged to a disengaged position.
When the drive member includes rotor vanes integrally moulded with the resilient jaws then movement of the release means from a first (rest) position to a second (release) position preferably urges the rotor vanes away from the air inlet thereby causing jaws to move from an engaged to a disengaged position. When the release means transports the capsule from an engaged to a disengaged position, the release means preferably includes an ejection arm which is adapted to urge the capsule out of the mounting means and through the air inlet. In a first (rest) position the ejection arm will be retracted from the mounting means an upon movement to a second (release) position will slide up inside the mounting means thereby ejecting the capsule. Movement of the ejection arm may be effected by an expulsion collar slidably mounted on the drive member.
When the device according to the invention includes release means movement of the release means from a first to a second position is preferably effected by a sleeve slidably mounted on the housing. The sleeve preferably performs the dual function of moving the release means and actuating piercing means. Therefore, in a preferred embodiment of the device, movement of the sleeve from a rest position in a direction parallel to the longitudinal axis of housing actuates piercing means for piercing a capsule held in the mounting means; and movement of the sleeve from the rest position in the opposite direction moves the release means from a first position to a second position.
When the device comprises release means this is preferably biased into a - first position, i.e a rest position in which a capsule can be inserted into, and engaged by, the mounting means.
The device may, if desired, be fitted with a non-return valve so that air may only be inhaled and not blown through the device by the patient.
The device may be constructed of any suitable material, preferably of a synthetic thermoplastic resin, e.g. high density polyethylene, acrylonitrile butadiene styrene (ABS), or DELRIN™; in which case it can be made by an injection moulding technique.
Although the device according to the invention has thus far been described for use in oral inhalation of medicaments, it is also suitable for the administration of nasal medicaments by inhalation. The necessary adaptation for this mode of administration will be readily apparent to those skilled in the art.
The capsules for use with the device according to the invention are preferably cylindrical, they may be made from any material which can be pierced, e.g. gelatin.
The device may be used for dispensing any powdered medicament which is conventionally administered by inhalation to the lung or nose. Such medicaments include drugs for use in the prophylactic or remedial treatment of reversible obstructive airways disease. Specific medicaments which may be mentioned include, for example, sodium cromoglycate and nedocromil sodium; inhaled steroids such as beclomethasone dipropionate, tipredane, and fluticasone; anticholinergic agents such as ipratropium bromide; bronchodilators, e.g. salmeterol, salbutamol, reproterol, terbutaline, albuterol and fenoterol; and salts thereof. If desired a mixture of medicaments, for example a mixture of sodium cromoglycate and a bronchodilator, such as reproterol or a salt thereof, may be used.
Devices according to the invention have advantages over known inhalation devices in that the procedures for insertion of the medicament capsule into the device, and for removal of the empty capsule from the device after inhalation, are considerably simplified. Furthermore, since the device does not need to be dismantled for insertion/removal of the capsule, the patient is less likely to inadvertently injure themselves on the piercing means; and the propeller-like member, if freely mounted on the shaft, cannot fall off the shaft during the insertion/removal procedure.
The invention will now be described, by way of example only, with reference to the accompanying drawings, in which:
Figure 1 is a perspective view of a device according to the invention;
Figure 2 is a longitudinal section of the device of Figure 1 in the rest position;
Figure 3 is a section along the line III-III of Figure 2; Figure 4 is a longitudinal section of the device of Figure 1 in the release position;
Figure 5 is a perspective view of an alternative device according to the invention;
Figure 6 is a longitudinal section of the device of Figure 5 in the rest position;
Figure 7 is a section along the line VII- VII of Figure 6; and
Figure 8 is a longitudinal section of the device of Figure 5 in the release position;
In the Figures corresponding features of the alternative devices are given the same reference numeral.
Referring firstly to Figures 1 to 4: a medicament inhalation device comprises a generally cylindrical housing (1) describing a through-going pathway. The housing (1) is provided at one end with a mouthpiece portion (2), optionally having a removable mouthpiece cover (not shown), and provided at the other end with an air inlet (3).
A shaft (4) is rigidly mounted coaxially with the housing (1), the end of shaft (4) adjacent to the mouthpiece (2) end of housing (1) being supported by cross members (5). Propeller (6) having a sleeve-like bearing (7) is mounted on shaft (4). Shaft (4) is provided with a circumferential recess (8) which receives a circumferential ridge (9) formed on the interior wall of bearing (7) such that dissociation of the shaft (4) and the propeller (6) is prevented. Propeller (6) is provided with a capsule mounting cup (10) comprising four resilient segments (11), shown best in Figure 3, which is adapted of engage a capsule (12) containing powdered medicament to be inhaled. Propeller (6) is also provided with four rotor vanes (13) integrally moulded with segments (11), which cause the propeller (6) to rotate on shaft (4) when air is drawn through the pathway, as during inhalation. .. Two stainless steel piercing needles (14), spring biased into the rest position s shown in Figures 2, are provided on housing (1). One end of each needle (14) being secured to the housing (1), the other end being curved inwards such that they point towards a capsule (12) engaged by segments (11) of cup (10). A sleeve (15) is slidably mounted on housing (1). Cam surfaces (16) located on the inside of sleeve
(15) are adapted to engage piercing needles (14) thus pushing them into a capsule o (12) engaged by segments (11) of cup (10) when the sleeve (15) is slid in the direction of arrow A in Figure 2. (The cam surfaces may be integrally moulded with the sleeve, however, for ease of manufacture they may be moulded separately and located in the sleeve during assembly of the device).
At the air inlet (3) end of housing (1) sleeve (15) turns inwards on itself thus s defining the walls of the air inlet (3). Sleeve (15) extends further within housing (1) to form a circular release collar (17) which is located between the air inlet (3) and rotor vanes (13). When sleeve (15) is moved in the direction of arrow C in Figure 4 the collar (17) is adapted to apply downwards pressure onto rotor vanes (13) thus urging them away from the air inlet (3), thereby causing the segments (11) of cup 0 (10) to splay outwards. In this position the air inlet end of sleeve (15) urges needles (14) slightly inwards against their bias, this effect may be further enhanced by the provision of cam surfaces within the sleeve.
In use, a capsule (12) containing powdered medicament to be inhaled is inserted through air inlet (3) and engaged by the segments (11) of cup (10). Sleeve 5 (15) is then moved in the direction of arrow A in Figure 2 causing the cam surfaces
(16) to engage needles (14) and pierce capsule (12). Reciprocal movement of the sleeve (15) allows needles (14) to withdraw from the pierced capsule (12) under thei spring bias.
The patient then inhales through mouthpiece (2), thereby drawing air 0 through the pathway in the direction of arrow B in Figure 2. The flow of air through the pathway causes the propeller (6) to rotate about shaft (4) and also to vibrate. The medicament is thereby dispensed from capsule (12) through the apertures formed by needles (14), entrained in the air flow and inhaled by the patient. Once the patient has inhaled the medicament, the device is held with the air inlet (3) pointing downwards and sleeve (15) is moved over housing (1) in the direction of arrow C in Figure 4 (this may be achieved by pushing the sleeve and .. mouthpiece towards each other). Release collar (17) presses onto rotor vanes (13), s the pressure on rotor vanes (13) causing segments (11) to splay outwards from the base of cup (10) thus disengaging the empty capsule (12) which falls out of the housing (1) through the air inlet, as shown in Figure 4. The sleeve (15) then returns to its rest position under the bias of needles (14) and the inhalation device is once more ready for use. o In an alternative embodiment of the device shown in Figures 5 to 8 the release means includes a cylindrical ejection collar (18) slidably mounted around the housing (1). The collar (18) is provided with projecting lugs (19) which cooperate with corresponding lugs (20) provided on the inside of sleeve (15). Ejection collar (18) is also provided with two transverse arms (21) which project into housing (1). s Arms (21) abut against the base of a secondary ejection collar (22) slidably mounted around sleeve-like bearing (7). The secondary ejection collar (22) has two arms (23) running parallel to bearing (7) which extend through the base of mounting cup (10). Ejection collar (18) is biased into the rest position shown in Figure 6 by spring (24). In use, a capsule (12) containing medicament to be inhaled is inserted o through air inlet (3) and engaged by the segments (11) of cup (10). Sleeve (15) is then moved in the direction of arrow D in Figure 6 causing the cam surfaces (16) to engage needles (14) and pierce capsule (12). Once the medicament has been inhaled by the patient, sleeve (15) is moved in the direction of arrow E in Figure 8, lugs (19, 20) slide the ejection collar (18) over housing (1) against the bias of spring 5 (24). The arms (21) of the ejection collar (18) push the secondary ejection collar (22) up the bearing (4) and arms (23) are raised into cup (10) thereby ejecting the empty capsule (12) out of the housing (1) through the air inlet (23). The sleeve (15) then returns to its rest position under the bias of spring (24) and the inhalation device is once more ready for use.

Claims

1. A medicament inhalation device includes a housing (1) defining a through- going pathway provided at one end with an air inlet (3), and at the other end with a mouthpiece (2); a drive member (6) rotatably mounted in the housing (1) on a shaft s (4) which is coaxial with the longitudinal axis of the housing (1), the drive member (6) having, on a portion adjacent to the air inlet (3), mounting means (10) adapted to engage a medicament capsule (12), and the drive member (6) being so mounted on the shaft (4) that the passage of a stream of air through the pathway causes rotational and vibrational movement of the drive member (6); characterised in that o the air inlet (3) is adapted to act as a capsule port through which a capsule (12) can be inserted into the mounting means (10).
2. A medicament inhalation device according to claim 1, wherein the device includes release means (17) to permit removal of a capsule (12) from the mounting means (10) through the air inlet (3). s
3. A medicament inhalation device according to claim 2, wherein the mounting means (10) includes resilient jaws (11) adapted to engage a medicament capsule (12) and movement of the release means (17) from a first position to a second position disengages the capsule (12) from the mounting means (10).
4. A medicament inhalation device according to claim 3, wherein movement of 0 the release means (17) from a first position to a second position moves the jaws (11) from an engaged to a disengaged position.
5. A medicament inhalation device according to claim 4, wherein the drive member (6) includes rotor vanes (13) integrally moulded with the resilient jaws (11) of the mounting means (10), and movement of the release means (17) from a first to 5 a second position urges the rotor vanes (13) away from the air inlet (3) thereby causing jaws (11) to move from an engaged to a disengaged position.
6. A medicament inhalation device according to claim 3, wherein movement of the release means (17) upon moving from a first to a second position transports the capsule (12) from an engaged to a disengaged position. 0
7. A medicament inhalation device according to claim 6, wherein the release means includes an ejection arm (23) adapted to urge the capsule (12) out of the mounting means (10) and through the air inlet (3).
8. A medicament inhalation device according to any one of the preceding claims, wherein movement of the release means (17) from a first to a second position is effected by a sleeve (15) slidably mounted on the housing (1).
9. A medicament inhalation device according to claim 6, wherein movement of the sleeve (15) from a rest position in a direction parallel to the longitudinal axis of housing (1) actuates piercing means (14) for piercing a capsule (12) held in the mounting means (10); and movement of the sleeve (15) from the rest position in the opposite direction moves the release means (17) from a first to a second position.
10. A medicament inhalation device according to any one of the preceding claims, in which the release means (17) is biased into the first position.
PCT/GB1993/002013 1992-09-23 1993-09-23 Inhalation device WO1994006498A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU48295/93A AU4829593A (en) 1992-09-23 1993-09-23 Inhalation device

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9220077.3 1992-09-23
GB929220077A GB9220077D0 (en) 1992-09-23 1992-09-23 Inhalation device
GB9220083.1 1992-09-23
GB929220083A GB9220083D0 (en) 1992-09-23 1992-09-23 Inhalation device

Publications (1)

Publication Number Publication Date
WO1994006498A1 true WO1994006498A1 (en) 1994-03-31

Family

ID=26301671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/002013 WO1994006498A1 (en) 1992-09-23 1993-09-23 Inhalation device

Country Status (2)

Country Link
AU (1) AU4829593A (en)
WO (1) WO1994006498A1 (en)

Cited By (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0755276A1 (en) * 1994-04-14 1997-01-29 Dura Pharmaceuticals, Inc. Dry powder inhaler
EP0796628A2 (en) * 1996-03-21 1997-09-24 Unisia Jecs Corporation Inhaler
WO1998030263A1 (en) 1997-01-09 1998-07-16 Sepracor, Inc. Multiple-dose dispenser for dry powder inhalers
US5947118A (en) * 1993-06-03 1999-09-07 Boehringer Ingelheim Kg Capsule holder
US5996577A (en) * 1995-08-11 1999-12-07 Unisia Jecs Corporation Medicine administering apparatus
US6089228A (en) * 1994-09-21 2000-07-18 Inhale Therapeutic Systems Apparatus and methods for dispersing dry powder medicaments
WO2002024266A1 (en) * 2000-09-25 2002-03-28 Microdrug Ag Foil cutter
WO2004002417A2 (en) 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
US6679256B2 (en) 1999-12-17 2004-01-20 Nektar Therapeutics Systems and methods for extracting powders from receptacles
WO2005097175A2 (en) 2004-03-31 2005-10-20 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
US7252087B2 (en) 2003-11-08 2007-08-07 Boehringer Ingelheim International Gmbh Powder inhaler
WO2007118800A1 (en) * 2006-04-11 2007-10-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mouthpiece for an inhaler
WO2007118858A1 (en) * 2006-04-15 2007-10-25 Boehringer Ingelheim International Gmbh Inhaler
WO2008021237A1 (en) 2006-08-10 2008-02-21 Arubor Corporation Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
US7456288B2 (en) 2003-10-28 2008-11-25 Reddy Us Therapeutics, Inc. Heterocyclic compounds and methods of making and using thereof
EP2090657A2 (en) 2000-08-07 2009-08-19 Centocor Ortho Biotech Inc. Anti-IL-12 antibodies, compositions, methods and uses
WO2009139733A1 (en) * 2008-05-16 2009-11-19 Mahmut Bilgic Dry powder inhalation device
EP2123675A2 (en) 2003-09-30 2009-11-25 Centocor Ortho Biotech Inc. Human EPO mimentic hinge core mimetibodies, compositions, methods and uses
EP2159230A1 (en) 2000-08-07 2010-03-03 Centocor Ortho Biotech Inc. Anti-TNF antibodies, compositions, methods and uses
WO2010051274A2 (en) 2008-10-31 2010-05-06 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
WO2010093627A2 (en) 2009-02-12 2010-08-19 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
WO2010111485A1 (en) 2009-03-25 2010-09-30 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
US7833531B2 (en) 2006-12-21 2010-11-16 Centocor, Inc. Method for treating insulin sensitivity by long-acting GLP-1 receptor mimetibody agonists
EP2253646A1 (en) 2000-08-07 2010-11-24 Centocor Ortho Biotech Inc. Anti-dual integrin antibody and compositions and conjugates comprising said antibody
EP2308888A1 (en) 2001-11-14 2011-04-13 Centocor Ortho Biotech Inc. Anti-IL-6 antibodies, compositions, methods and uses
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
EP2452694A1 (en) 2005-06-30 2012-05-16 Janssen Biotech, Inc. Anti-IL-23 antibodies, compositions, methods and uses
WO2012175735A1 (en) 2011-06-23 2012-12-27 Vib Vzw A20 inhibitors for the treatment of respiratory viral infections
EP2548577A1 (en) 2005-12-29 2013-01-23 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, methods and uses
US8481053B2 (en) 2002-02-13 2013-07-09 Immunology Laboratories, Inc. Compositions and methods for treating of microbial infections
WO2014106459A2 (en) 2013-01-07 2014-07-10 Superlab Far East Limited A method for treating tumor by using recombinant interferon with changed spatial configuration
WO2014135224A1 (en) * 2013-03-08 2014-09-12 Interquim, S.A. Inhaler
WO2014144763A2 (en) 2013-03-15 2014-09-18 Memorial Sloan Kettering Cancer Center High affinity anti-gd2 antibodies
US8875701B2 (en) 2006-04-11 2014-11-04 Boehringer Ingelheim International Gmbh Inhaler
EP2842968A1 (en) 2005-04-29 2015-03-04 Janssen Biotech, Inc. Anti-IL-6 antibodies, compositions, methods and uses
KR20160116056A (en) 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 Anti-il-12/il-23 antibodies
EP3138601A1 (en) * 2015-09-04 2017-03-08 Victor Esteve Dry powder inhaler
WO2018014038A1 (en) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Chimeric antigen receptors and methods for use
WO2018014039A1 (en) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Chimeric antigen receptors (cars) specific for muc1 and methods for their use
WO2018087699A2 (en) 2016-11-09 2018-05-17 The Board Of Regents Of The University Of Texas System Methods and compositions for adaptive immune modulation
EP3323830A1 (en) 2010-06-19 2018-05-23 Memorial Sloan-Kettering Cancer Center Anti-gd2 antibodies
WO2018112037A1 (en) 2016-12-16 2018-06-21 Jia Zhou Inhibitors of bromodomain-containing protein 4 (brd4)
WO2018115915A1 (en) * 2016-12-20 2018-06-28 Emphasys Importadora Exportadora E Distribuidora Ltda. Dry powder inhaler
WO2018140026A1 (en) 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
EP1399105B2 (en) 2001-06-13 2018-09-05 Boehringer Ingelheim Pharma GmbH & Co.KG Method for cleaning hard gelatine capsules
US10286065B2 (en) 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
WO2019126574A1 (en) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Vcar compositions and methods for use
WO2019215701A1 (en) 2018-05-11 2019-11-14 Janssen Biotech, Inc. Methods of treating depression using il-23 antibodies
WO2020148651A1 (en) 2019-01-15 2020-07-23 Janssen Biotech, Inc. Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
WO2020152544A1 (en) 2019-01-23 2020-07-30 Janssen Biotech, Inc. Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
WO2020183270A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
WO2020183269A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
WO2020183271A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
WO2020245677A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
WO2020245676A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
US11014982B2 (en) 2017-02-07 2021-05-25 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
US11041020B2 (en) 2017-01-30 2021-06-22 Janssen Biotech, Inc. Methods for the treatment of active Psoriatic Arthritis
WO2021211628A1 (en) 2020-04-14 2021-10-21 Poseida Therapeutics, Inc. Compositions and methods for use in the treatment of cancer
WO2021214588A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating coronavirus infections
WO2021214587A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating viral infections
WO2022026943A2 (en) 2020-07-31 2022-02-03 Pinetree Therapeutics, Inc. Neuropilin and angiotensin converting enzyme 2 fusion peptides for treating viral infections
US11389433B2 (en) 2018-06-18 2022-07-19 Board Of Regents, The University Of Texas System BRD4 inhibitor treatment of IgE-mediated diseases
WO2023279115A1 (en) 2021-07-02 2023-01-05 Henry Ford Health System Compositions comprising endosidin 2 for reducing sars-cov-2 infection
WO2023281462A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
WO2023281463A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
EP4190817A1 (en) 2015-03-17 2023-06-07 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
EP3986514A4 (en) * 2019-06-24 2023-08-09 De Motu Cordis Pty Ltd Automatic dispenser for respiratory delivery device
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH461035A (en) * 1966-09-17 1968-08-15 Fisons Pharmaceuticals Ltd Device for oral inhalation of drugs in finely divided form
GB1268051A (en) * 1968-06-07 1972-03-22 Fisons Pharmaceuticals Ltd Inhalation device
FR2380032A1 (en) * 1977-02-10 1978-09-08 Allen & Hanburys Ltd CAPSULE INHALER

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH461035A (en) * 1966-09-17 1968-08-15 Fisons Pharmaceuticals Ltd Device for oral inhalation of drugs in finely divided form
GB1268051A (en) * 1968-06-07 1972-03-22 Fisons Pharmaceuticals Ltd Inhalation device
FR2380032A1 (en) * 1977-02-10 1978-09-08 Allen & Hanburys Ltd CAPSULE INHALER

Cited By (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5947118A (en) * 1993-06-03 1999-09-07 Boehringer Ingelheim Kg Capsule holder
EP0755276A4 (en) * 1994-04-14 1998-04-01 Dura Pharma Inc Dry powder inhaler
EP0755276A1 (en) * 1994-04-14 1997-01-29 Dura Pharmaceuticals, Inc. Dry powder inhaler
US6089228A (en) * 1994-09-21 2000-07-18 Inhale Therapeutic Systems Apparatus and methods for dispersing dry powder medicaments
US5996577A (en) * 1995-08-11 1999-12-07 Unisia Jecs Corporation Medicine administering apparatus
EP0796628A2 (en) * 1996-03-21 1997-09-24 Unisia Jecs Corporation Inhaler
EP0796628A3 (en) * 1996-03-21 1998-05-06 Unisia Jecs Corporation Inhaler
WO1998030263A1 (en) 1997-01-09 1998-07-16 Sepracor, Inc. Multiple-dose dispenser for dry powder inhalers
US5794613A (en) * 1997-01-09 1998-08-18 Sepracor, Inc. Multiple-dose dispenser for dry powder inhalers
US6679256B2 (en) 1999-12-17 2004-01-20 Nektar Therapeutics Systems and methods for extracting powders from receptacles
EP2330129A2 (en) 2000-08-07 2011-06-08 Centocor Ortho Biotech Inc. Anti-TNF antibodies, compositions, methods and uses
EP3118318A1 (en) 2000-08-07 2017-01-18 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, methods and uses
EP2305817A2 (en) 2000-08-07 2011-04-06 Centocor Ortho Biotech Inc. Anti-IL-12 antibodies, compositions, methods and uses
EP2253646A1 (en) 2000-08-07 2010-11-24 Centocor Ortho Biotech Inc. Anti-dual integrin antibody and compositions and conjugates comprising said antibody
EP3597752A1 (en) 2000-08-07 2020-01-22 Janssen Biotech, Inc. Anti-il-12 antibodies, compositions, methods and uses
EP2090657A2 (en) 2000-08-07 2009-08-19 Centocor Ortho Biotech Inc. Anti-IL-12 antibodies, compositions, methods and uses
EP2159230A1 (en) 2000-08-07 2010-03-03 Centocor Ortho Biotech Inc. Anti-TNF antibodies, compositions, methods and uses
WO2002024266A1 (en) * 2000-09-25 2002-03-28 Microdrug Ag Foil cutter
EP1399105B2 (en) 2001-06-13 2018-09-05 Boehringer Ingelheim Pharma GmbH & Co.KG Method for cleaning hard gelatine capsules
EP2308888A1 (en) 2001-11-14 2011-04-13 Centocor Ortho Biotech Inc. Anti-IL-6 antibodies, compositions, methods and uses
US9539292B2 (en) 2002-02-13 2017-01-10 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
US9962434B2 (en) 2002-02-13 2018-05-08 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
US8481053B2 (en) 2002-02-13 2013-07-09 Immunology Laboratories, Inc. Compositions and methods for treating of microbial infections
US9241984B2 (en) 2002-02-13 2016-01-26 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
US9511101B2 (en) 2002-02-13 2016-12-06 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
US8518416B2 (en) 2002-02-13 2013-08-27 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
US9072694B2 (en) 2002-02-13 2015-07-07 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
US8920815B2 (en) 2002-02-13 2014-12-30 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
WO2004002417A2 (en) 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
EP2123675A2 (en) 2003-09-30 2009-11-25 Centocor Ortho Biotech Inc. Human EPO mimentic hinge core mimetibodies, compositions, methods and uses
US7456288B2 (en) 2003-10-28 2008-11-25 Reddy Us Therapeutics, Inc. Heterocyclic compounds and methods of making and using thereof
US7252087B2 (en) 2003-11-08 2007-08-07 Boehringer Ingelheim International Gmbh Powder inhaler
WO2005097175A2 (en) 2004-03-31 2005-10-20 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
EP2842968A1 (en) 2005-04-29 2015-03-04 Janssen Biotech, Inc. Anti-IL-6 antibodies, compositions, methods and uses
EP2452694A1 (en) 2005-06-30 2012-05-16 Janssen Biotech, Inc. Anti-IL-23 antibodies, compositions, methods and uses
EP3501537A1 (en) 2005-06-30 2019-06-26 Janssen Biotech, Inc. Anti-il23 antibodies, compositions, methods and uses
EP3219328A1 (en) 2005-12-29 2017-09-20 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, method and uses
EP2548577A1 (en) 2005-12-29 2013-01-23 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, methods and uses
EP3760230A1 (en) 2005-12-29 2021-01-06 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, methods and uses
US8875701B2 (en) 2006-04-11 2014-11-04 Boehringer Ingelheim International Gmbh Inhaler
WO2007118800A1 (en) * 2006-04-11 2007-10-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mouthpiece for an inhaler
US8281784B2 (en) 2006-04-11 2012-10-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mouthpiece for an inhaler
EP2656867A3 (en) * 2006-04-11 2014-01-22 Boehringer Ingelheim Pharma GmbH & Co. KG Mouthpiece for an inhalator
JP2009533112A (en) * 2006-04-11 2009-09-17 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Inhaler mouthpiece
JP2009533192A (en) * 2006-04-15 2009-09-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Inhaler
WO2007118858A1 (en) * 2006-04-15 2007-10-25 Boehringer Ingelheim International Gmbh Inhaler
US8196578B2 (en) 2006-04-15 2012-06-12 Boehringer Ingelheim International Gmbh Inhaler
US11718853B2 (en) 2006-08-10 2023-08-08 Onspira Therapeutics, Inc. Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
EP3669878A1 (en) 2006-08-10 2020-06-24 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
WO2008021237A1 (en) 2006-08-10 2008-02-21 Arubor Corporation Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
US7833531B2 (en) 2006-12-21 2010-11-16 Centocor, Inc. Method for treating insulin sensitivity by long-acting GLP-1 receptor mimetibody agonists
WO2009139733A1 (en) * 2008-05-16 2009-11-19 Mahmut Bilgic Dry powder inhalation device
KR20160116056A (en) 2008-08-14 2016-10-06 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 Anti-il-12/il-23 antibodies
WO2010051274A2 (en) 2008-10-31 2010-05-06 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
EP3128048A1 (en) 2008-10-31 2017-02-08 Janssen Biotech, Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
WO2010093627A2 (en) 2009-02-12 2010-08-19 Centocor Ortho Biotech Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
US9186400B2 (en) 2009-03-25 2015-11-17 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
WO2010111485A1 (en) 2009-03-25 2010-09-30 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
US8883174B2 (en) 2009-03-25 2014-11-11 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
US9504742B2 (en) 2009-03-25 2016-11-29 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
US10722573B2 (en) 2009-03-25 2020-07-28 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
EP4269563A2 (en) 2010-06-19 2023-11-01 Memorial Sloan-Kettering Cancer Center Anti-gd2 antibodies
EP3323830A1 (en) 2010-06-19 2018-05-23 Memorial Sloan-Kettering Cancer Center Anti-gd2 antibodies
WO2012175735A1 (en) 2011-06-23 2012-12-27 Vib Vzw A20 inhibitors for the treatment of respiratory viral infections
WO2014106459A2 (en) 2013-01-07 2014-07-10 Superlab Far East Limited A method for treating tumor by using recombinant interferon with changed spatial configuration
EP3895725A2 (en) 2013-01-07 2021-10-20 Superlab Far East Limited A method for treating tumor by using recombinant interferon with changed spatial configuration
WO2014135224A1 (en) * 2013-03-08 2014-09-12 Interquim, S.A. Inhaler
WO2014144763A2 (en) 2013-03-15 2014-09-18 Memorial Sloan Kettering Cancer Center High affinity anti-gd2 antibodies
US10286065B2 (en) 2014-09-19 2019-05-14 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
EP4190817A1 (en) 2015-03-17 2023-06-07 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
EP3138601A1 (en) * 2015-09-04 2017-03-08 Victor Esteve Dry powder inhaler
WO2018014038A1 (en) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Chimeric antigen receptors and methods for use
WO2018014039A1 (en) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Chimeric antigen receptors (cars) specific for muc1 and methods for their use
US11826422B2 (en) 2016-11-09 2023-11-28 Board Of Regents, The University Of Texas System Methods and compositions for adaptive immune modulation
WO2018087699A2 (en) 2016-11-09 2018-05-17 The Board Of Regents Of The University Of Texas System Methods and compositions for adaptive immune modulation
US11117865B2 (en) 2016-12-16 2021-09-14 Board Of Regents, The University Of Texas System Inhibitors of bromodomain-containing protein 4 (BRD4)
WO2018112037A1 (en) 2016-12-16 2018-06-21 Jia Zhou Inhibitors of bromodomain-containing protein 4 (brd4)
WO2018115915A1 (en) * 2016-12-20 2018-06-28 Emphasys Importadora Exportadora E Distribuidora Ltda. Dry powder inhaler
US11517686B2 (en) 2016-12-20 2022-12-06 Emphasys Importadora Exportadora E Distribuidora Ltda. Dry powder inhaler
WO2018140026A1 (en) 2017-01-27 2018-08-02 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
US11041020B2 (en) 2017-01-30 2021-06-22 Janssen Biotech, Inc. Methods for the treatment of active Psoriatic Arthritis
US11014982B2 (en) 2017-02-07 2021-05-25 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
WO2019126574A1 (en) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Vcar compositions and methods for use
WO2019215701A1 (en) 2018-05-11 2019-11-14 Janssen Biotech, Inc. Methods of treating depression using il-23 antibodies
US11389433B2 (en) 2018-06-18 2022-07-19 Board Of Regents, The University Of Texas System BRD4 inhibitor treatment of IgE-mediated diseases
WO2020148651A1 (en) 2019-01-15 2020-07-23 Janssen Biotech, Inc. Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
WO2020152544A1 (en) 2019-01-23 2020-07-30 Janssen Biotech, Inc. Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
WO2020183269A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
WO2020183270A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
WO2020183271A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
WO2020245676A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
WO2020245677A1 (en) 2019-06-03 2020-12-10 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
EP3986514A4 (en) * 2019-06-24 2023-08-09 De Motu Cordis Pty Ltd Automatic dispenser for respiratory delivery device
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
WO2021211628A1 (en) 2020-04-14 2021-10-21 Poseida Therapeutics, Inc. Compositions and methods for use in the treatment of cancer
WO2021214588A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating coronavirus infections
WO2021214587A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating viral infections
WO2022026943A2 (en) 2020-07-31 2022-02-03 Pinetree Therapeutics, Inc. Neuropilin and angiotensin converting enzyme 2 fusion peptides for treating viral infections
WO2023279115A1 (en) 2021-07-02 2023-01-05 Henry Ford Health System Compositions comprising endosidin 2 for reducing sars-cov-2 infection
WO2023281463A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
WO2023281462A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions

Also Published As

Publication number Publication date
AU4829593A (en) 1994-04-12

Similar Documents

Publication Publication Date Title
WO1994006498A1 (en) Inhalation device
KR100321814B1 (en) Dry powder inhaler
US5787881A (en) Inhalation device
KR0177265B1 (en) Dry powder inhaler
KR100218816B1 (en) Powder inhaler
RU2393883C1 (en) Simple inhaler
KR100323942B1 (en) Medicine Inhaler and Inhalation Method
RU2332240C2 (en) Doser cartridge with preliminary measuring of dry inhalator powder
US5243970A (en) Dosing device for administering metered amounts of powdered medicaments to patients
JP5651233B2 (en) Simple capsule-based inhaler
FI67026C (en) ANDNINGSAKTIVERAD ANORDNING FOER ORAL INHALATION AV POWDER FORM CEILINGS
US4116195A (en) Device for dispensing medicaments
US9050427B2 (en) Dry powder inhalers with multi-facet surface deagglomeration chambers and related devices and methods
JPH04227269A (en) Dosing device for powder medicine
JPH08509626A (en) Inhaler
WO2007093310A2 (en) Dry powder inhaler device
JPH0147190B2 (en)
CN105916491B (en) Inhalable medicaments
JP2001524363A (en) Dry powder inhaler
JPH06509958A (en) powder dispenser
JPH08103499A (en) Inhalation type medicine administrator
US20130025593A1 (en) Dry powder inhaler
JPH05505738A (en) drug inhalation device
WO2002089875A1 (en) Powder deaggregation device

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642